Aims: Current therapy fails to emulate rapid (first-phase) insulin release in relation to a meal, a key defect in types 1 and 2 diabetes. We aimed to quantify the pharmacokinetic (PK) and pharmacodynamic (PD) profile of insulin tregopil, an enterically-absorbed insulin analog that restores the normal distribution of insulin between the hepatic portal and peripheral circulations.
| INTRODUCTION
Despite being one of the earliest and most significant pathophysiological abnormalities in the natural history of type 1 1 and type 2 diabetes 2,3 (T1DM and T2DM), the loss of first-phase insulin release is not corrected by current therapy. In the physiologic state, a burst of insulin secretion is observed within 10 minutes in response to an increase in plasma glucose concentrations. 4 This first-phase insulin response promptly inhibits hepatic glucose production (HGP) and is critical in controlling postprandial hyperglycaemia. 5, 6 Unfortunately, current therapy fails to reproduce two key elements of the firstphase insulin response: rapid absorption into the plasma and physiologic distribution between the hepatic portal and peripheral circulations.
Virtually all patients with T1DM and many patients with T2DM
rely on subcutaneously delivered, rapid-acting insulin analogs to suppress HGP and promote glucose disposal during and after eating.
Whereas physiological first-phase insulin release results in a rapid rise in plasma insulin concentration within 10 minutes post-prandially, 45 to 120 minutes are required to reach a maximum concentration after subcutaneous delivery of rapid-acting insulin analogs. [6] [7] [8] Because insulin arrival at the liver is slower than normal, modulation of HGP is delayed, resulting in larger postprandial hyperglycaemic excursions. 4 An additional drawback to subcutaneous insulin delivery is that individuals with diabetes deliver the hormone directly into the peripheral circulation rather than, more physiologically, into the hepatic portal circulation. As a result, patients relying on subcutaneous insulin delivery "over-insulinize" the peripheral circulation while "under-insulinizing" the liver. This iatrogenic peripheral hyperinsulinaemia appears to contribute to hypoglycaemia, 9 weight gain 10 and insulin resistance.
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Enteric insulin delivery has the potential both to restore an appropriate balance of insulin between the liver and peripheral tissues and to exhibit rapid absorption kinetics. As described in detail elsewhere, 12 tregopil (IN-105 in previous studies) is a novel insulin analog modified for oral delivery by the addition of a single shortchain amphiphilic oligomer at the Lys-β29 residue of recombinant human insulin. In a dose-finding study, tregopil, given at mealtimes to participants with T2DM, resulted in a rapid time-to-peak concentration (t max ) of 30 minutes. 12 In the present study, we sought to further characterize tregopil's pharmacokinetic (PK) and pharmacodynamic 2 | METHODS
| Experimental design
The biological characteristics of insulin tregopil were studied in four parts.
| Part 1: Comparison of the bioeffectiveness of human insulin vs insulin tregopil
The objective of Part 1 was to compare the effectiveness of recombinant human insulin and tregopil in altering glucose metabolism when infused at equimolar rates into the hepatic portal vein, the site of entry into the blood after oral delivery. Dogs were fed a chow diet daily and were fasted 18 hours prior to being studied. The experimental protocol consisted of a 40-minute control period followed by two 120-minute test periods. Somatostatin was infused through a peripheral vein at 0.8 μg/kg/min to block endogenous hormone production by the endocrine pancreas and glucagon was infused intra-portally at a rate equivalent to its normal basal secretion rate (0.57 ng/kg/min).
In one group (n = 7) human insulin was infused intra-portally at 3.6 pmol/kg/min (600 μU/kg/min) for 120 minutes, and then at 12.0 pmol/kg/min (2000 μU/kg/min) for 120 minutes. In the second group (n = 6), insulin tregopil was infused intra-portally at the same rates as those used for human insulin. 
| Processing and analysis of samples
Blood samples were collected and processed as described in detail elsewhere. 13, 19, 20 Plasma insulin concentrations were determined by radioimmunoassay. Standard curves of human insulin and tregopil were compared and were found to be only minimally different in the range of insulin concentrations studied. In experiments in which oral tregopil was administered, endogenous insulin production was somewhat suppressed as indicated by the decline in plasma c-peptide levels, making the contribution of endogenous insulin to the total insulin levels less than 30 pmol/L (5 μU/mL).
| Calculations and statistical analysis
Data are presented as means AE standard error of the mean (SEM) unless indicated otherwise. Net hepatic substrate balances (NHB), non-hepatic glucose uptake and hepatic sinusoidal hormone concentrations were calculated as described elsewhere. [21] [22] [23] A positive number for net hepatic glucose balance (NHGB) represents net hepatic glucose output, whereas a negative value represents net hepatic glucose uptake. Area under the curve (AUC) was calculated by trapezoidal approximation. Change in AUC (ΔAUC) was determined by subtracting AUC for the parameter of interest minus the average basal concentration, normalized to equivalent time intervals.
To assess the bioequivalence of intraportal tregopil with human insulin, mean PK and PD data were assessed by calculating proportions (human insulin divided by tregopil) and differences (human insulin minus tregopil) for key PK/PD results from Parts 1 and 3 of the study. A 90% confidence interval for the ratio of means was calculated using Fieller's theorem, 24 in keeping with FDA guidance. 25 Confidence intervals of proportions and differences were calculated using the by comparison to data from a previous study. 26 In the prior experiment, DiCostanzo et al. administered a bolus of human insulin into the portal vein of six dogs over 5 minutes at a rate of 10 mU/kg/min (300 pmol/kg). This study was chosen because the plasma arterial insulin concentration vs time curves were similar to the tregopil protocols. The estimated bioavailability of oral tregopil relative to an intraportal dose of human insulin is given as: 3 | RESULTS
| Part 1: Comparison of the bioeffectiveness of human insulin vs insulin tregopil
Pharmacokinetic and pharmacodynamic results for equivalent intraportal infusions of tregopil and human insulin are summarized in Table 1 and depicted in Figure 1 . Arterial plasma insulin concentrations during the final 30 minutes of each infusion period and AUC in insulin for each period were slightly higher with tregopil compared to human insulin ( Figure 1A ). This corresponds to whole-body insulin clearance being modestly lower for tregopil relative to human insulin.
Arterial and hepatic sinusoidal glucagon concentrations (data not shown) were basal and did not differ between groups.
Despite slightly higher arterial plasma insulin concentrations with tregopil during period 1, the GIRs required to maintain euglycaemia were nearly identical between the two groups ( Figure 1D and Table 1 ). During period 2 the insulin infusion rate was increased to 12.0 pmol/kg/min, again resulting in modestly higher concentrations of tregopil than human insulin; however, the GIR was again the same with the two insulins. At the liver, both insulins caused a similar change in NHGB ( Figure 1E ). Likewise, non-hepatic glucose uptake increased similarly in both groups ( Figure 1F ).
| Part 2: Determination of the dose-response relationship for tregopil
After orogastric gavage the PK profile for the 0.0625-and 0.125-mg/ kg doses was similar, with no statistically significant difference for insulin C max , t max , AUC 0 -120 or ΔAUC 0 -45 between the two (Table S1 and Figure 2A ). The PD profile (GIR AUC 0 -120 , GIR max , and t GIRmax ) of the lower two doses differed minimally ( Figure 2B ). When the larger 0.25-mg/kg dose was compared against the lower two doses, however, statistically significant differences were seen for C max , insulin AUC 0-120 , insulin ΔAUC 0-45 , GIR AUC 0-120 and GIR max . By virtue of the clamp, no significant difference in arterial plasma glucose existed between the groups ( Figure 2C ).
The estimated relative bioavailability of the 0.25-mg/kg (41.5 nmol/kg) oral dose of liquid tregopil was 0.82% when compared to an intra-portal bolus of human insulin (300 pmol/kg), which had a similar PK profile in the arterial plasma. Similar pharmacokinetic profiles were found between the first and second treatments when 3-mg and 6-mg tablets were given as shown in Figure 3A ,B and Figure S1A ,C. When individual pharmacokinetic parameters were assessed, the first 3-mg dose was associated with a slightly lower mean C max (88%) and mean insulin AUC 0-120 (79%) compared with the second 3-mg dose (Table S2) . On the other hand, a higher Cmax and insulin AUC 0-120 were seen with the first 6-mg dose compared with the second 6-mg dose (117% and 118%, respectively).
There was no difference in C max and AUC 0-120 of tregopil between the first doses of 3 mg and 6 mg. The 10-mg tablet was associated with an increased response relative to the lower doses. Additionally, there was increased variability and significantly higher C max and insulin AUC 0-120 with the first dose compared with the second dose ( Figure 3C and Table S2 ). A t max of 20 minutes was frequently observed with all doses (Table S2 ).
The PD profile between the first and second treatment with each dose was similar, but not identical ( Figure 3D ,F and The estimated relative bioavailability of the 6-mg (45.0 nmol/kg) oral dose of tregopil in tablet form was 0.85% as compared to the 300 pmol/kg intraportal human insulin bolus. 26 
| Part 4: Comparison of pharmacokinetic and pharmacodynamic characteristics of oral tregopil against subcutaneous and inhaled insulin
The average insulin C max was slightly (15%) lower with liquid oral insulin tregopil compared with inhaled insulin and subcutaneous insulin (Table S4 ). The rapid median t max was similar between oral insulin tregopil and inhaled insulin (20 min), while the median t max with subcutaneous insulin was considerably slower (88 min). Although C max was nearly similar with the three delivery routes, when compared to oral insulin, tregopil GIR max was 3.7-fold higher for subcutaneous insulin 4.1 | When tregopil and human insulin were delivered to the hepatic portal vein at equivalent molar rates, their PK profiles were quite similar and their PD profiles were virtually equivalent During Part 1, there was a tendency towards reduced clearance of tregopil as compared with human insulin, resulting in modestly higher arterial plasma tregopil concentrations. Tregopil's effect on the liver, to lower NHGB, and on non-hepatic tissues, to stimulate glucose uptake, was comparable to that of human insulin. It follows that the GIRs required to maintain euglycaemia were almost equivalent between tregopil and human insulin. Collectively, this implies that, while tregopil's clearance rate is somewhat reduced relative to that of human insulin, this effect is pharmacodynamically offset by a small increase in tregopil's levels and effect on target tissues. Because the GIRs for the two groups were not at a steady state at completion of the study, it is uncertain whether the PD profiles would have remained nearly equivalent for a longer time.
4.2 | A threshold amount of enteric liquid tregopil needs to be exceeded to achieve a significant PD effect 
| There was reasonable PK and PD reproducibility for consecutive doses of tregopil
Increased intra-subject and inter-subject variability has limited broad acceptance of oral insulin to date. In large part, this can be attributed to increased intra-subject and inter-subject variability in the response to oral insulin. During Part 3, successive doses of tregopil resulted in similar, but not identical, PK and PD profiles. The 6-mg dose of tregopil had the best reproducibility, where the ratios between the first and second treatment for C max , arterial plasma insulin AUC 0-120 and GIR 
FIGURE 3 Pharmacokinetic and pharmacodynamic profiles from successive enteric doses of tregopil. Following an overnight fast, dogs ingested two identical doses of either 3, 6 or 10 mg tablets with 120 minutes separating the first and second doses (Part 3). Note: Y-axis scale differs with 10-mg dose for arterial plasma insulin C, and glucose infusion rate F. Data are presented as mean values bounded by the 90% CI AUC 0-120 ranged between 0.9 and 1.2. The 10-mg dose was associated with a larger degree of variability in the arterial plasma insulin profile and in GIR, with higher insulin concentrations with the first dose, but with an earlier and larger peak GIR with the second dose.
While not bioequivalent, these data provide early evidence suggesting tregopil's viability as an adjunctive therapy to reduce postprandial hyperglycaemia. Tregopil could feasibly supplement rapid-acting subcutaneous insulin in T1DM and endogenous insulin production AE exogenous insulin in T2DM. Rapid clearance kinetics and first-pass hepatic extraction of tregopil conceivably would dampen and diminish the effect of variable absorption on glucose uptake in peripheral tissues. Additional studies will be needed, however, to characterize the intra-individual variability in tregopil's PK/PD profile. In this investigation, the dogs receiving enteric tregopil had been fasted for at least 18 hours prior to study. Clearly, the dosing time before a meal, the interval between meals, the meal content and other clinical factors will influence absorption kinetics significantly 27 and will have to be assessed.
4.4 | The PK and PD profiles of oral insulin tregopil were equally or more rapid than those resulting from inhaled and subcutaneous insulin delivery
In our analysis comparing the three routes of insulin delivery, in which roughly similar insulin C max values were reached, tregopil had a t max that was the same as that for inhaled insulin and was shorter than that for subcutaneous insulin. Further, both t GIRmax and the time needed Further studies in humans will also need to clarify whether tregopil should complement or replace subcutaneous prandial insulin.
In the fasted dogs we tested, enterically delivered insulin had rapid t max times (≤20 min in most cases) and off-times (≤120 min).
Although the rapid t max would likely blunt early hyperglycaemia, patients lacking endogenous insulin production would continue absorbing nutrients beyond the rapid tregopil off-time, 32 resulting in late hyperglycaemia. If tregopil exhibited similar kinetics in these patients, they would still require subcutaneous prandial insulin to avoid late hyperglycaemia. Whether the PK/PD profile is favourably modified by pre-meal dose timing, between-meal intervals and meal content is an area of active investigation. Clinical studies should analyse the cost-to-benefit ratio of a treatment regimen that might reduce postprandial hyperglycaemia at the expense of more complex meal dosing.
Another concern is the limited bioavailability of oral insulin formulations to date, which ultimately increases the cost of achieving a needed pharmacological effect. In the present study, the relative bioavailabilities of tregopil in liquid (0.25 mg/kg) and tablet (6 mg = 0.26 mg/kg) forms were 0.82% and 0.85%, respectively. The decreased bioavailability additionally suggests that substantial amounts of tregopil remain in the gastrointestinal tract. Although gastrointestinal proteases and peptidases probably degrade much of the intraluminal insulin, no studies have determined how quickly this occurs with tregopil. Because of several studies that have correlated high insulin levels with oncologic risk, [33] [34] [35] long-term surveillance seems prudent.
In conclusion, these studies show that enterically delivered insulin tregopil achieves two key therapeutic advancements towards mimicking physiological insulin release: rapid entry into the plasma and a physiological portal-to-peripheral insulin distribution. These characteristics hold promise for mitigating postprandial hyperglycaemia by supplementing subcutaneous prandial insulin therapy in T1DM and endogenous insulin secretion in T2DM, and exogenous insulin in many cases. Clinical studies of tregopil are needed to quantify tregopil's ability to reduce postprandial hyperglycaemia and to further characterize intra-individual and inter-individual PK and PD variability in "real-life" settings.
